Meta-analysis shows GLP-1 RAs improve functional walking distance and reduce major adverse limb events and lower extremity amputations in type 2 diabetes patients with peripheral artery disease.
Walk further, keep limbsGLP-1 drugs improved functional walking distance and reduced amputation risk in diabetic PAD patients
What the researchers found
GLP-1 RAs associated with improved functional walking distance, reduced MALE, and lower amputation rates in T2D patients with PAD.
Why it matters
PAD-related amputations are devastating and often preventable. GLP-1 drugs improving walking distance means better quality of life and potentially fewer amputations.
How the study worked
Systematic review and meta-analysis evaluating GLP-1 RA effects on walking distance, MALE, and amputations in T2D patients with PAD.
What this study cannot tell us
Most evidence observational. Heterogeneity across studies. Cannot determine optimal GLP-1 drug or dose for PAD.
How to read the evidence
Systematic review and meta-analysis providing pooled evidence. Mostly observational studies included.
When this study was published
Published in 2025.
The bigger picture
GLP-1 drugs protect blood vessels throughout the body — from heart to brain to legs — suggesting they address fundamental vascular biology.
Questions still open
- Should GLP-1 drugs become standard care for all diabetic PAD patients?
- Is the walking improvement clinically meaningful for daily life?
- Do the benefits extend to non-diabetic PAD patients?
Common questions
Can GLP-1 drugs help with leg circulation problems?
Should PAD patients take GLP-1 drugs?
Read the original research
GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies.
Diabetes, obesity & metabolism
Citation
Giugliano, Dario; Longo, Miriam; Di Martino, Nicole; Scappaticcio, Lorenzo; Caruso, Paola; Bellastella, Giuseppe; Maiorino, Maria Ida; Esposito, Katherine. (2026). GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies.. Diabetes, obesity & metabolism. https://doi.org/10.1111/dom.70454